The faculty and administration of the University of Utah propose to continue development of a Cancer Research Center, firmly based on our strengths in cancer research (molecular, cellular, genetic, epidemiological, pre-therapy, and therapy) and certain unusual demographic characteristics of our region and its population. The scientific programs involve over 80 funded Investigator-members In 3 schools and colleges of the University and 4 Salt Lake city hospitals. The overall goal of the Cancer Center is to contribute to the national effort to decrease the morbidity and mortality of cancer. The means by which we propose to approach this goal can be stated as our objectives. 1. Facilitate and stimulate interdisciplinary research by providing an academic and administrative link among investigators. 2. Strengthen existing research programs by providing support for core equipment and services used by multiple investigators. 3. Strengthen our programs by assisting in recruitment of faculty to add our strengths and to fill current gaps in expertise. 4. Facilitate transfer from the laboratory to the clinic new findings which may reduce the incidence of cancer, facilitate its early detection, or improve its treatment. 5. Provide a scientific environment attractive for graduate research education and develop financial support for graduate students, the future leaders in cancer research. 6. Develop improved and augmented facilities for cancer research. The interdepartmental center will derive financial support from a variety of institutional, state, private and federal sources, including this Cancel Support Grant.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA042014-06
Application #
3101808
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1986-07-01
Project End
1994-04-30
Budget Start
1991-05-01
Budget End
1992-04-30
Support Year
6
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of Utah
Department
Type
Schools of Medicine
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Pishas, Kathleen I; Drenberg, Christina D; Taslim, Cenny et al. (2018) Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. Mol Cancer Ther 17:1902-1916
Blackburn, Brenna E; Ganz, Patricia A; Rowe, Kerry et al. (2018) Reproductive and gynecological complication risks among thyroid cancer survivors. J Cancer Surviv 12:702-711
Wu, Yelena P; Aspinwall, Lisa G; Nagelhout, Elizabeth et al. (2018) Development of an Educational Program Integrating Concepts of Genetic Risk and Preventive Strategies for Children with a Family History of Melanoma. J Cancer Educ 33:774-781
Kim, Hyung-Seok; McKnite, Autumn; Xie, Yuanyuan et al. (2018) Fibronectin type III and intracellular domains of Toll-like receptor 4 interactor with leucine-rich repeats (Tril) are required for developmental signaling. Mol Biol Cell 29:523-531
Spiker, William Ryan; Brodke, Darrel S; Goz, Vadim et al. (2018) Evidence of an Inherited Predisposition for Spinal Cord Tumors. Global Spine J 8:340-344
Ye, Zhizhou; Ayer, Donald E (2018) Ras Suppresses TXNIP Expression by Restricting Ribosome Translocation. Mol Cell Biol :
Fuller, Andrew K; Bice, Benjamin D; Venancio, Ashlee R et al. (2018) A Method to Define the Effects of Environmental Enrichment on Colon Microbiome Biodiversity in a Mouse Colon Tumor Model. J Vis Exp :
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Faham, Najme; Zhao, Ling; Welm, Alana L (2018) mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential. NPJ Breast Cancer 4:36
Rengifo-Cam, William; Shepherd, Hailey M; Jasperson, Kory W et al. (2018) Colon Pathology Characteristics in Li-Fraumeni Syndrome. Clin Gastroenterol Hepatol 16:140-141

Showing the most recent 10 out of 1193 publications